Researchers at RCSI University of Medicine and Health Sciences have developed a low-cost, synthetic mitral valve model that replicates the mechanical properties of human heart tissue under physiological pressure. The innovation allows for precise testing of valve repair strategies in a laboratory setting, offering a new method to study mitral regurgitation, a condition affecting millions globally, according to the study published in Acta Biomaterialia.
How does the new synthetic valve replicate human tissue?
The model distinguishes itself by incorporating anisotropy, the property of having different mechanical strengths in different directions, which is essential to native heart valve function. According to Dr. Claire Conway of the RCSI Department of Anatomy and Regenerative Medicine, previous synthetic models failed to withstand the high-pressure environments found in the human heart. By capturing these specific mechanical behaviors, the RCSI team created a device that functions under realistic flow conditions while remaining cost-effective for research applications.
The human mitral valve performs an incredible feat of endurance, opening and closing approximately 100,000 times every single day to regulate blood flow.
Why is this model significant for treating mitral regurgitation?
Mitral regurgitation occurs when the heart valve fails to close properly, causing blood to leak backward. Because many cases of the condition are rooted in the degradation of valve mechanics, having a physical model that behaves like human tissue provides a controlled environment for testing repairs. Dr. Sina Javadpour, a postdoctoral fellow at Trinity College Dublin and the study’s first author, notes that the model offers precise control over leaflet tension and thickness, enabling researchers to simulate how malfunctions begin and progress in a clinical setting.
How does this compare to previous valve testing methods?
Historically, researchers have struggled to bridge the gap between simple benchtop models and expensive, complex animal or human cadaver studies. While traditional synthetic models lacked the durability to handle physiological pressure, the RCSI model provides a repeatable, low-cost alternative. The following table highlights the shift in testing capabilities:
| Feature | Traditional Synthetic Models | RCSI Mechano-mimetic Model |
|---|---|---|
| Mechanical Anisotropy | Lacking | Included |
| Pressure Handling | Limited | Physiological |
| Cost | Variable | Low-cost |
What are the future implications for cardiac surgery?
The ability to precisely calibrate valve leaflets suggests a future where surgeons could use patient-specific models to test repair strategies before entering the operating room. The research, funded by the RCSI StAR Lectureship and the Research Ireland Frontiers for the Future Programme, moves the field closer to personalized cardiac medicine. By refining the fabrication process, the team has ensured that these models are consistent, which is a requirement for clinical validation.
For those interested in seeing this technology firsthand, the model valves are currently on display at the Heart exhibition in the Humanarium at RCSI.
Frequently Asked Questions
What is mitral regurgitation?
It is a condition where the mitral valve does not close tightly, allowing blood to leak backward into the heart, which can lead to reduced heart efficiency.
Why is anisotropy important in heart valves?
Anisotropy ensures the valve has different mechanical properties in different directions, allowing it to withstand the specific, multi-directional stresses of a beating heart.
Can these models be used for human implantation?
No, this model is designed specifically for laboratory research, disease modeling, and testing surgical repair strategies, not for clinical implantation in patients.
Are you interested in the latest breakthroughs in regenerative medicine? Subscribe to our newsletter to receive updates on cardiovascular research and medical technology directly to your inbox.
